Disruption of the intestinal mucosal barrier in Candida albicans infections

Microbiological Research

Volumn 168, Issue 7, 2013, Pages 389-395

  Yan, Lei ^a   Yang, Chunhui ^a   Tang, Jianguo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Candida albicans; Infection; Mechanism; The intestinal mucosal barrier

Indexed keywords

ALBICANS; ANTIFUNGAL DRUGS; CANDIDA ALBICANS; CRITICALLY ILLS; INFECTION; MORTALITY RATE; MUCOSAL BARRIERS; VIRULENCE FACTORS;

MECHANISMS; YEAST;

CANDIDA;

FUNGAL PROTEIN; VIRULENCE FACTOR;

COLONIZATION; DISEASE; FUNGUS; IMMUNITY; MICROORGANISM; MORPHOLOGY; MORTALITY; VIRULENCE; YEAST;

ANIMAL; CANDIDA ALBICANS; CANDIDIASIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; REVIEW;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; HUMANS; INTESTINAL MUCOSA; VIRULENCE FACTORS;

CANDIDA ALBICANS;

EID: 84878500995     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2013.02.008     Document Type: Review

References (95)

1. Argimón S., Fanning S., Blankenship J.R., Mitchell A.P. Interaction between the Candida albicans high-osmolarity glycerol (HOG) pathway and the response to human beta-defensins 2 and 3. Eukaryot Cell 2011, 10:272-275.
2. Bai X.D., Liu X.H., Tong Q.Y. Intestinal colonization with Candida albicans and mucosal immunity. World J Gastroenterol 2004, 10:2124-2126.
3. Bareiss P.M., Metzger M., Sohn K., Rupp S., Frick J.S., Autenrieth I.B., et al. Organotypical tissue cultures from adult murine colon as an in vitro model of intestinal mucosa. Histochem Cell Biol 2008, 129:795-804.
4. Bassetti M., Taramasso L., Nicco E., Molinari M.P., Mussap M., Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 2011, 6:e24198.
5. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34:1269-1281.
6. Braun B.R., Johnson A.D. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 1997, 277:105-109.
7. Braun B.R., Johnson A.D. TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida. Genetics 2000, 155:57-67.
8. Braun B.R., Kadosh D., Johnson A.D. NRG1, a repressor of filamentous growth in C. albicans, is down-regulated during filament induction. EMBO J 2001, 20:4753-4761.
9. Brzozowski T., Zwolinska-Wcislo M., Konturek P.C., Kwiecien S., Drozdowicz D., Konturek S.J., et al. Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol 2005, 40:286-296.
10. Bujdáková H., Paulovicová E., Borecká-Melkusová S., Gasperík J., Kucharíková S., Kolecka A., et al. Antibody response to the 45kDa Candida albicans antigen in an animal model and potential role of the antigen in adherence. J Med Microbiol 2008, 57:1466-1472.
11. Coates E.W., Karlowicz M.G., Croitoru D.P., Buescher E.S. Distinctive distribution of pathogens associated with peritonitis in neonates with focal intestinal perforation compared with necrotizing enterocolitis. Pediatrics 2005, 116:e241-e246.
12. Coste A., Lagane C., Filipe C., Authier H., Galès A., Bernad J., et al. IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation. J Immunol 2008, 180:4939-4947.
13. Czerkinsky C., Anjuere F., McGhee J.R., George-Chandy A., Holmgren J., Kieny M.P., et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999, 170:197-222.
14. de Repentigny L., Aumont F., Bernard K., Belhumeur P. Characterization of binding of Candida albicans to small intestinal mucin and its role in adherence to mucosal epithelial cells. Infect Immun 2000, 68:3172-3179.
15. Douglas L.J. Candida biofilms and their role in infection. Trends Microbiol 2003, 11:30-36.
16. Drummond R.A., Brown G.D. The role of Dectin-1 in the host defence against fungal infections. Curr Opin Microbiol 2011, 14:392-399.
17. Feng Y.W., Wu M., Li Y., Zeng J.J., Li M.L., He Y., et al. Significance of identification of fungi in gastric juice of patients with artificial airway in intensive care unit. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012, 24:96-99.
18. Finkel J.S., Mitchell A.P. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 2011, 9:109-118.
19. Fortun-Lamothe L., Boullier S. A review on the interactions between gut micro flora and digestive mucosal immunity. Possible ways to improve the health of rabbits. Livest Sci 2007, 107:1-18.
20. Frank C.F., Hostetter M.K. Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. Transl Res 2007, 149:211-222.
21. Galès A., Conduché A., Bernad J., Lefevre L., Olagnier D., Béraud M., et al. PPAR gamma controls dectin-1 expression required for host antifungal defense against Candida albicans. PLoS Pathog 2010, 6:e1000714.
22. Ganguly S., Bishop A.C., Xu W., Ghosh S., Nickerson K.W., Lanni F., et al. Zap1 control of cell-cell signaling in Candida albicans biofilms. Eukaryot Cell 2011, 10:1448-1454.
23. Garbino J., Lew D.P., Romand J.A., Hugonnet S., Auckenthaler R., Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo- controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28:1708-1717.
24. Gow N.A., Perera T.H., Sherwood-Higham J., Gooday G.W., Gregory D.W., Marshall D. Investigation of touch-sensitive responses by hyphae of the human pathogenic fungus Candida albicans. Scanning Microsc 1994, 8:705-710.
25. Hagey L.R., Vidal N., Hofmann A.F., Krasowski M.D. Complex evolution of bile salts in birds. Auk 2010, 127:820-831.
26. Hashimoto M., Hirota K., Yoshitomi H., Maeda S., Teradaira S., Akizuki S., et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med 2010, 207:1135-1143.
27. Hofmann A.F., Hagey L.R. Bileacids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008, 65:2461-2483.
28. Hu X., He D. Advances in the research of Intestinal mucosal bio-barrier. China Med Eng 2010, 18:173-176.
29. Jin L., Yoshida M., Nakamura T., Ishikawa H., Wakabayashi G., Tanabe M., et al. Candida albicans infection delays duodenal ulcer healing in cysteamine-induced duodenal ulcers in rats. Dig Dis Sci 2008, 53:2878-2885.
30. Kadosh D., Johnson A.D. Rfg1, a protein related to the Saccharomyces cerevisiae hypoxic regulator Rox1, controls filamentous growth and virulence in Candida albicans. Mol Cell Biol 2001, 21:2496-2505.
31. Kadosh D., Johnson A.D. Induction of the Candida albicans filamentous growth program by relief of transcriptional repression: a genome-wide analysis. Mol Biol Cell 2005, 16:2903-2912.
32. Kao C.Y., Chen Y., Thai P., Wachi S., Huang F., Kim C., et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol 2004, 173:3482-3491.
33. Kelly M.T., MacCallum D.M., Clancy S.D., Odds F.C., Brown A.J., Butler G. The Candida albicans CaACE2 gene affects morphogenesis, adherence and virulence. Mol Microbiol 2004, 53:969-983.
34. Koh A.Y., Köhler J.R., Coggshall K.T., Van Rooijen N., Pier G.B. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008, 4:e35.
35. Kolida S., Saulnier D.M., Gibson G.R. Gastrointestinal microflora: probiotics. Adv Appl Microbiol 2006, 59:187-219.
36. Kong W., Wang J., Xing X., Xiao X., Zhao Y., Zang Q., et al. Antifungal evaluation of cholic acid and its derivatives on Candida albicans by microcalorimetry and chemometrics. Anal Chim Acta 2011, 689:250-256.
37. Kumari A., Catanzaro R., Marotta F. Clinical importance of lactic acid bacteria: a short review. Acta Biomed 2011, 82:177-180.
38. Lane S., Birse C., Zhou S., Matson R., Liu H. DNA array studies demonstrate convergent regulation of virulence factors by Cph1, Cph2, and Efg1 in Candida albicans. J Biol Chem 2001, 276:48988-48996.
39. Lane S., Zhou S., Pan T., Dai Q., Liu H. The basic helix-loop-helix transcription factor Cph2 regulates hyphal development in Candida albicans partly via TEC1. Mol Cell Biol 2001, 21:6418-6428.
40. Leberer E., Harcus D., Broadbent I.D., Clark K.L., Dignard D., Ziegelbauer K., et al. Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans. Proc Natl Acad Sci U S A 1996, 93:13217-13222.
41. Lefèvre L., Galès A., Olagnier D., Bernad J., Perez L., Burcelin R., et al. PPAR γ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination. PLoS One 2010, 5:e12828.
42. Li F., Palecek S.P. Distinct domains of the Candida albicans adhesin Eap1p mediate cell-cell and cell-substrate interactions. Microbiology 2008, 154:1193-1203.
43. Liu H., Kohler J., Fink G.R. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 1994, 266:1723-1726.
44. Lo H.J., Kohler J.R., DiDomenico B., Loebenberg D., Cacciapuoti A., Fink G.R. Nonfilamentous C. albicans mutants are avirulent. Cell 1997, 90:939-949.
45. Luongo D., D'Arienzo R., Bergamo P., Maurano F., Rossi M. Immunomodulation of gut-associated lymphoid tissue: current perspectives. Int Rev Immunol 2009, 28:446-464.
46. Mailänder-Sánchez D., Wagener J., Schaller M. Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. Mycoses 2012, 55:17-26.
47. Miranda L.N., van der Heijden I.M., Costa S.F., Sousa A.P., Sienra R.A., Gobara S., et al. Candida colonisation as a source for candidaemia. J Hosp Infect 2009, 72:9-16.
48. Molloy M.J., Bouladoux N., Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol 2012, 24:58-66.
49. Monroy-Perez E., Sainz-Espunes T., Paniagua-Contreras G., Negrete-Abascal E., Rodríguez-Moctezuma J.R., Vaca S. Frequency and expression of ALS and HWP1 genotypes in Candida albicans strains isolated from Mexican patients suffering from vaginal candidosis. Mycoses 2012, 55:e151-e157.
50. Montalto M., D'Onofrio F., Gallo A., Cazzato A., Gasbarrini G. Intestinal microbiota and its functions. Dig Liver Dis Suppl 2009, 3:30-34.
51. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
52. Murad A.M., Leng P., Straffon M., Wishart J., Macaskill S., MacCallum D., et al. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J 2001, 20:4742-4752.
53. Nagi M., Tanabe K., Takano Y., Kikuchi K., Miyazaki Y., Niimi M. Serum or bile affects the in vitro azole susceptibilities of Candida spp. Jpn J Infect Dis 2009, 62:306-308.
54. Naglik J.R., Challacombe S.J., Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003, 67:400-428.
55. Nailis H., Kucharíková S., Ricicová M., Van Dijck P., Deforce D., Nelis H., et al. Real-time PCR expression profiling of genes encoding potential virulence factors in Candida albicans biofilms: identification of model-dependent and -independent gene expression. BMC Microbiol 2010, 10:114.
56. Nakamura T., Yoshida M., Ishikawa H., Kameyama K., Wakabayashi G., Otani Y., et al. Candida albicans aggravates duodenal ulcer perforation induced by administration of cysteamine in rats. J Gastroenterol Hepatol 2007, 22:749-756.
57. Nantel A., Dignard D., Bachewich C., Harcus D., Marcil A., Bouin A.P., et al. Transcription profiling of Candida albicans cells undergoing the yeast-to-hyphal transition. Mol Biol Cell 2002, 13:3452-3465.
58. Nobile C.J., Mitchell A.P. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol 2005, 15:1150-1155.
59. Nobile C.J., Nett J.E., Hernday A.D., Homann O.R., Deneault J.S., Nantel A., et al. Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 2009, 7:e1000133.
60. Nucci M., Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001, 33:1959-1967.
61. O'Brien R.L., Roark C.L., Born W.K. IL-17-producing gammadelta T cells. Eur J Immunol 2009, 39:662-666.
62. O'Flaherty S., Klaenhammer T.R. The role and potential of probiotic bacteria in the gut, and the communication between gut microflora and gut/host. Int Dairy J 2010, 20:262-268.
63. Oh S., Go G.W., Mylonakis E., Kim Y. The bacterial signalling molecule indole attenuates the virulence of the fungal pathogen Candida albicans. J Appl Microbiol 2012, 113:622-628.
64. Peltroche-Llacsahuanga H., Goyard S., D'Enfert C., Prill S.K., Ernst J.F. Protein o-mannosyltransferase isoforms regulate biofilm formation in Candida albicans. Antimicrob Agents Chemother 2006, 50:3488-3491.
65. Peyrin-Biroulet L., Beisner J., Wang G., Nuding S., Oommen S.T., Kelly D., et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010, 107:8772-8777.
66. Polonelli L., Ciociola T., Magliani W., Zanello P.P., D'Adda T., Galati S., et al. Peptides of the constant region of antibodies display fungicidal activity. PLoS One 2012, 7:e34105.
67. Pultz N.J., Stiefel U., Ghannoum M., Helfand M.S., Donskey C.J. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother 2005, 49:438-440.
68. Ramage G., Bachmann S., Patterson T.F., Wickes B.L., Lopez-Ribot J.L. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002, 49:973-980.
69. Romeo M.G., Romeo D.M., Trovato L., Oliveri S., Palermo F., Cota F., et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011, 31:63-69.
70. Rosenbach A., Dignard D., Pierce J.V., Whiteway M., Kumamoto C.A. Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryot Cell 2010, 9:1075-1086.
71. Safdar N., Said A., Lucey M.R. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. Liver Transpl 2004, 10:817-827.
72. Samonis G., Kofteridis D.P., Maraki S., Alegakis D., Mantadakis E., Papadakis J.A., et al. Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 2005, 49:5189.
73. Samonis G., Mantadakis E., Barbounakis E., Kofteridis D., Papadakis G., Sifaki L., et al. Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans. Mycoses 2008, 51:324-327.
74. Schulze J., Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int 2009, 106:837-842.
75. Schweizer A., Rupp S., Taylor B.N., Röllinghoff M., Schröppel K. The TEA/ATTS transcription factor CaTec1p regulates hyphal development and virulence in Candida albicans. Mol Microbiol 2000, 38:435-445.
76. Stoldt V.R., Sonneborn A., Leuker C.E., Ernst J.F. Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J 1997, 16:1982-1991.
77. Sudbery P.E. Growth of Candida albicans hyphae. Nat Rev Microbiol 2011, 9:737-748.
78. Taff H.T., Nett J.E., Zarnowski R., Ross K.M., Sanchez H., Cain M.T., et al. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog 2012, 8:e1002848.
79. Thompson D.S., Carlisle P.L., Kadosh D. Coevolution of morphology and virulence in Candida species. Eukaryot Cell 2011, 10:1173-1182.
80. Tournu H., Van Dijck P. Candida biofilms and the host: models and new concepts for eradication. Int J Microbiol 2012, 2012:845352.
81. van de Veerdonk F.L., Kullberg B.J., Netea M.G. Adjunctive immunotherapy with recombinant cytokines for the treatment of disseminated candidiasis. Clin Microbiol Infect 2012, 18:112-119.
82. van de Veerdonk F.L., Marijnissen R.J., Kullberg B.J., Koenen H.J., Cheng S.C., Joosten I., et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009, 5:329-340.
83. van den Berg L.M., Gringhuis S.I., Geijtenbeek T.B. An evolutionary perspective on C-type lectins in infection and immunity. Ann N Y Acad Sci 2012, 1253:149-158.
84. van der Meer J.W., van de Veerdonk F.L., Joosten L.A., Kullberg B.J., Netea M.G. Severe Candida spp. infections: new insights into natural immunity. Int J Antimicrob Agents 2010, 36(Suppl. 2):58-62.
85. van Till J.O., van Ruler O., Lamme B., Weber R.J., Reitsma J.B., Boermeester M.A. Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review. Crit Care 2007, 11:R126.
86. Varnum M.M., Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 2012, 60:251-266.
87. Vediyappan G., Rossignol T., D'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob Agents Chemother 2010, 54:2096-2111.
88. Vu B., Essmann M., Larsen B. Sodium choleate (NaCho) effects on Candida albicans: implications for its role as a gastrointestinal tract inhabitant. Mycopathologia 2010, 169:183-191.
89. Wang Y., Xu X.L. Bacterial peptidoglycan-derived molecules activate Candida albicans hyphal growth. Commun Integr Biol 2008, 1:137-139.
90. Wang Y.C., Huang S.H., Lan C.Y., Chen B.S. Prediction of phenotype-associated genes via a cellular network approach: a Candida albicans infection case study. PLoS One 2012, 7:e35339.
91. Xu X.L., Lee R.T., Fang H.M., Wang Y.M., Li R., Zou H., et al. Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host Microbe 2008, 4:28-39.
92. Yen C.C., Lin C.Y., Chong K.Y., Tsai T.C., Shen C.J., Lin M.F., et al. Lactoferrin as a natural regimen for selective decontamination of the digestive tract: recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogenic challenge in the gastrointestinal tract. J Infect Dis 2009, 199:590-598.
93. Zandstra D.F., Van Saene H.K. Selective decontamination of the digestive tract as infection prevention in the critically ill. A level 1 evidence-based strategy. Minerva Anestesiol 2011, 77:212-219.
94. Zhu W., Filler S.G. Interactions of Candida albicans with epithelial cells. Cell Microbiol 2010, 12:273-282.
95. Zwolińska-Wcisło M., Brzozowski T., Mach T., Budak A., Trojanowska D., Konturek P.C., et al. Are probiotics effective in the treatment of fungal colonization of the gastrointestinal tract?. Experimental and clinical studies. J Physiol Pharmacol 2006, 57(Suppl. 9):35-49.